UK govt and pharma industry to start drug pricing negations next month
The Association of the British Pharmaceutical Industry (ABPI) and the UK Department of Health (DoH) on Friday published a joint statement on arrangements for pricing branded medicines from 2014.
The negotiations, which are set to begin in September, will determine the arrangements for pricing branded medicines in the UK from 2014, including medicines that are already on the market in December 2013 and new medicines which are launched from 1 January 2014.
The DoH and the ABPI says they are committed to reaching agreement on a pricing system that gives patients better access to the most effective medicines, at prices that encourage the National Health Service to use those medicines when clinicians think their patients can benefit and deliver value to the NHS, and provide a fair reward for these innovative medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze